FX125L: Phase I data

In a double-blind, placebo-controlled, multiple ascending-dose, U.S. Phase I trial in 36 healthy volunteers, 150, 500 and 1,500 mg doses of once-daily oral FX125L for 7 days were well tolerated with n...